● Human Immune Cell Marker Guide: cst-science.com/rkkb1f
● Mouse Immune Cell Marker Guide: cst-science.com/q2r8ud
Participating Experts: Elizabeth M Jaffe MD, Johns Hopkins University, and Matthew Galsky MD, Mount Sinai
Tumors are complex hubs of cellular activity that incorporate immune cells, vasculature, and even bacteria. It has become increasingly clear that a better understanding of this tumor microenvironment and the different types of immune cells within it is critical to developing more effective cancer therapies. In particular, immunotherapies that target the signaling mechanisms of T cells have shown great promise for many patients. However, these techniques have proven successful for only a fraction of people and against just a few cancer types. A detailed dissection of the molecular signaling switches that control immune cell activation and tumor checkpoint evasion is required if we hope to broaden the reach of immunotherapy treatments. Our speakers describe key signaling mechanisms and shed light on how they can be utilized to better activate and control immune cells in the tumor microenvironment.
About CST:
About CST®: Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high-quality research tools to the biomedical research community. Our employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan. cellsignal.com/about
All trademarks are the property of their respective owners. For the most up-to-date trademark information, please visit www.cellsignal.com/trademarks
#antibody